Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.prp.2021.153419 http://scihub22266oqcxt.onion/10.1016/j.prp.2021.153419 33857718!7997691!33857718     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pathol+Res+Pract 2021 ; 221 (ä): 153419 Nephropedia Template TP {{tp|p=33857718|t=2021. Endothelial-Mesenchymal Transition in COVID-19 lung lesions |pdf=|usr=}}{{33857718}} gab.com Text Endothelial-Mesenchymal Transition in COVID-19 lung lesions JO: Pathol Res Pract http://www.kidney.de/pget.php?&tw=1&pmid=33857718 #FOAvip Sars-Cov-2 infection is still a healthcare emergency and acute respiratory distress failure with Diffuse Alveolar Damage (DAD) features is the main causes of patients' death. Pathogenic mechanisms of the disease are not clear yet, but new insights are necessary to improve therapeutic management, to prevent fatal irreversible multi-organ damage and to adequately follow up those patients who survive. Here we investigated, by histochemistry and immunohistochemistry, a wide number of mapped lung specimens taken from whole body autopsies of 7 patients dead of COVID-19 disease. Our data confirm morphological data of other authors, and enlarge recent reports of the literature suggesting that Endothelial-Mesenchymal Transition might be central to COVID-19 lung fibrosing lesions. Furthermore, based upon recent acquisition of new roles in immunity and vascular pathology of the CD31 molecule, we hypothesize that this molecule might be important in the development and treatment of COVID-19 pulmonary lesions. These preliminary findings need further investigations to shed light on the complexity of Sars-Cov-2 disease. Twit Text FOAVip Endothelial-Mesenchymal Transition in COVID-19 lung lesions ????Pathol Res Pract http://www.kidney.de/pget.php?&tw=1&pmid=33857718 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33857718 #FOAvip English Wikipedia <ref>{{Cite pmid|33857718}}</ref> Endothelial-Mesenchymal Transition in COVID-19 lung lesions #MMPMID33857718 Falleni M; Tosi D; Savi F; Chiumello D; Bulfamante G Pathol Res Pract 2021[May]; 221 (ä): 153419 PMID33857718show ga Sars-Cov-2 infection is still a healthcare emergency and acute respiratory distress failure with Diffuse Alveolar Damage (DAD) features is the main causes of patients' death. Pathogenic mechanisms of the disease are not clear yet, but new insights are necessary to improve therapeutic management, to prevent fatal irreversible multi-organ damage and to adequately follow up those patients who survive. Here we investigated, by histochemistry and immunohistochemistry, a wide number of mapped lung specimens taken from whole body autopsies of 7 patients dead of COVID-19 disease. Our data confirm morphological data of other authors, and enlarge recent reports of the literature suggesting that Endothelial-Mesenchymal Transition might be central to COVID-19 lung fibrosing lesions. Furthermore, based upon recent acquisition of new roles in immunity and vascular pathology of the CD31 molecule, we hypothesize that this molecule might be important in the development and treatment of COVID-19 pulmonary lesions. These preliminary findings need further investigations to shed light on the complexity of Sars-Cov-2 disease. |*Epithelial-Mesenchymal Transition[MESH] |Aged[MESH] |COVID-19/*pathology[MESH] |Female[MESH] |Humans[MESH] |Lung Diseases/*pathology/*virology[MESH] |Male[MESH] |Middle Aged[MESH]Endothelial-Mesenchymal Transition in COVID-19 lung lesions (epmc).pdf DeepDyve Pubget Overpricing